Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Melanoma 13Multiple Myeloma 3Carcinoma, Renal Cell 3Neoplasms 2Colorectal Neoplasms 2Breast Neoplasms 2Uveal Melanoma 1Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Recurrence 1Peritoneal Neoplasms 1Pancreatic Neoplasms 1Neuroendocrine Tumors 1Neoplasms, Plasma Cell 1Neoplasm Metastasis 1Lymphoma, Follicular 1Lymphoma 1Lung Neoplasms 1Leukemia-Lymphoma, Adult T-Cell 1Leukemia 1Hematologic Neoplasms 1Breast Carcinoma In Situ 1

Interventions

Gemcitabine 43pembrolizumab 36Paclitaxel 36Nivolumab 31Docetaxel 29Capecitabine 29Bevacizumab 29Oxaliplatin 28Fluorouracil 28Cisplatin 26Leucovorin 24Cyclophosphamide 23Radiosurgery 20Irinotecan 20Carboplatin 20aldesleukin 19Cetuximab 19Interleukin-2 16fludarabine phosphate 15fludarabine 15Pemetrexed 15Trastuzumab 14Magnetic Resonance Spectroscopy 14Ipilimumab 14Fulvestrant 14130-nm albumin-bound paclitaxel 14Prednisone 13Everolimus 13Radiotherapy 12Panitumumab 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Neoplasm Metastasis × Introns × Clear all
NCT01545141 2023-10-27

Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer

Roswell Park Cancer Institute

Phase 1/2 Terminated
15 enrolled 9 charts
Gastrointestinal

Neoplasm Metastasis, Recurrence, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡